Balázs Judit, Besnyo Márta, Gádoros Júlia
Vadaskert Child and Adolescent Psychiatry Hospital and Outpatient Clinic, Budapest, Hungary.
J Child Adolesc Psychopharmacol. 2007 Jun;17(3):378-81. doi: 10.1089/cap.2006.0055.
In this paper, we report the case of a 6(1/2)-year-old male patient diagnosed with attention-deficit/hyperactivity disorder (ADHD) who developed orofacial and extremity dyskinesias immediately after methylphenidate treatment. The episode lasted 5 hours, peaking in intensity 2 hours after the medication was administered before gradually subsiding. Five hours after the methylphenidate was administered, the child became extremely irritated and aggressive, which lasted approximately 2 hours. The patient's general intelligence (IQ) was measured to be below the normal range. The potential relationship between methylphenidate intake and the development of dyskinesia calls into question different mechanisms involving drug-receptor interaction or individual drug sensitivity related to a lower IQ. Our case report has practical implications for physicians by raising their awareness of dyskinesia as a potential side effect of methylphenidate treatment.
在本文中，我们报告了一例6岁半男性患者，该患者被诊断患有注意力缺陷多动障碍（ADHD），在服用哌甲酯后立即出现口面部和肢体运动障碍。发作持续了5小时，在用药后2小时强度达到峰值，随后逐渐消退。服用哌甲酯5小时后，患儿变得极度烦躁和具有攻击性，这种情况持续了约2小时。该患者的一般智力（智商）经测量低于正常范围。哌甲酯摄入与运动障碍发展之间的潜在关系引发了对涉及药物 - 受体相互作用或与较低智商相关的个体药物敏感性的不同机制的质疑。我们的病例报告通过提高医生对运动障碍作为哌甲酯治疗潜在副作用的认识，对医生具有实际意义。
